Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2005

View Archived Issues

PET studies predict a very low abuse liability of a new antidepressant

In vivo evidence that PARP inhibitors reduce cardiac dysfunction during transplantation

Modulation of astrocytic function as an alternative approach for the treatment of schizophrenia

Interleukin-4 mediates inflammatory modulation of synaptic function in the hippocampus

TA-375 and TA-380 tested on stunned myocardium in dogs

Lorus Therapeutics signs collaboration agreement with Sumitomo and Koken

NIAID to test Tarvacin for antiviral potential

Yakult launches Elprat for colorectal cancer in Japan

Phase I/II study evaluates Inovio's DNA delivery technology in prostate cancer

Clickhaler asthma products receive approvals in European market

New patents describe therapeutic agents for psychiatric disorders

Novel monoclonal antibodies imparted by Biogen Idec for use in immunosuppression

A phase III study supports the use of rituximab in rheumatoid arthritis

Promising phase II results reported for belimumab in rheumatoid arthritis

Neuroprotective efficacy of repinotan hydrochloride, a 5-HT1A receptor agonist / News in Context

Transdermal methylphenidate shows efficacy in children with ADHD

Serono discontinues two phase III programs

INCB-7839 enters phase I trial

IND clearance allows phase I study of ZIO-101 in hematological cancers

GCS-100LE studied in phase I/II study for multiple myeloma

ImaRx studies Sonolysis in phase II stroke study

Argos' personalized melanoma vaccine studied in Germany

Phase II breast cancer study of KOS-862 to proceed

Enrollment completed in phase III study of Trisenox consolidation in APL

Siplizumab under investigation for CD2-positive lymphoproliferative disorders

Schwarz Pharma's rotigotine NDA accepted for filing

Celebrex gets boxed warning; Bextra suspended

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...